56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India

Background

The incidence of colorectal cancer (CRC) has increased among the younger population. Adolescents and young adults (AYA) are an important component of the active population in any country that impact the health care system along with socio-economic consequences. We present one of the first multicentre collaborative studies on AYA CRC from a low and middle-income country (LMIC).

Methods

The study was a multicentre retrospective registry conducted over the period of 3 years, from January 2018 to December 2020, after approval from respective IECs. A total of 126 AYA CRC Patients were enrolled in the study. The details regarding socio-demographic profile, histopathology, and therapeutic details were recorded.

Results

A total of 126 patients of AYA colorectal cancer patients were enrolled in the study between 2018 - 2020. 62.70% of patients had colon cancer, 37.30 % had rectal cancer. 50.79 % of patients were male. 67.46% of patients belong to 31-40 age group, with an average age of 32.6 years. Abdomen pain and distension (34%), and blood in stools (22%) were the most common presentations. On presentation, 31.75% had cTNM stage IV, 28.57% stage III, 15.87% stage II as per AJCC 8. 92(74.60%) underwent surgery, and adenocarcinoma (65.08 %) was the most common histology. 28.57% of patients were stage III on pTNM. Most of the patients were offered potentially curative therapy (65.87%), and 33.33% of patients were on palliative treatment. CAPOX was the most commonly prescribed chemotherapy regimen. MSI profiling was available only for eight patients.

Conclusions

As per our knowledge, this study is one of the first multicentre collaborative studies from an LMIC related to the clinic-pathological profile of AYA CRC patients. Most such patients present in non-metastatic stage, and potentially receive curative therapy. However, only a small minority could get MSI/mutational profiling.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Biotechnology Industry Research Assistance Council (BIRAC) India.

Disclosure

All authors have declared no conflicts of interest.